Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.
Continue reading here:
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland